EUVIMEDEUVIMED entdecken
Kohortenstudie

L26/P-695 Long-acting FSH (corifollitropin alfa) improves ovarian response in poor responders undergoing IVF: a propensity-matched cohort study

T.M.T. Luong, J.H. Lee, N.T. Ho, Y.M. Hwu, J.Y.P. Ho, R.S. Wang, S.J. Tan, Y.X. Lee, H.H. Huang, N.Q.K. Le, C.R. Tzeng

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1024 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von T.M.T. Luong und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Can single-dose corifollitropin alfa improve ovarian response while maintaining favorable pregnancy outcomes in poor ovarian responders undergoing IVF compared with daily gonadotropins? Summary answer Corifollitropin alfa significantly increased oocyte and embryo yield, with a trend toward improved pregnancy outcomes compared with daily stimulation in poor responders. What is known already Poor ovarian response (POR) remains a major challenge in assisted reproduction, leading to reduced stimulation efficiency and low pregnancy rates. Although daily gonadotropin injections are widely used, treatment burden, cost, and patient compliance remain concerns. Corifollitropin alfa (CFA), a long-acting follicle-stimulating hormone (FSH) analog, enables sustained follicular stimulation for up to seven days following a single injection. However, its role in POR patients remains controversial, as most evidence is derived from normal responders. Whether CFA can improve stimulation efficiency, oocyte yield, and pregnancy outcomes in Bologna-defined POR patients warrants further investigation. Study design, size, duration This retrospective cohort study included 1,113 poor ovarian responders undergoing 2,929 IVF cycles between March 2020 and May 2025. Inclusion required fulfillment of at least two Bologna criteria (antral follicle count (AFC) <5; anti-Mullerian hormone (AMH) <1.1 ng/mL; ≤3 oocytes retrieved previously; age >40 years). Propensity score matching (1:1) generated 158 CFA and 158 daily gonadotropin cycles for comparative analysis. Participants/materials, setting, methods Participants received either a single 150 μg subcutaneous dose of CFA (Group A, n = 300) or daily recombinant FSH/hMG (Group B, n = 2,629). Additional gonadotropins were administered from stimulation day 8 when necessary. Premature LH surges were prevented using antagonist or progestin protocols. Primary outcomes were total and metaphase II (MII) oocytes retrieved. Secondary outcomes included embryo development and pregnancy outcomes. Analyses were performed before and after matching. Main results and the role of chance Before matching, Group A had a higher AMH level than Group B (0.76±0.49 vs 0.60±0.45 ng/mL, p < 0.001). After matching, this difference was eliminated (p = 0.996), and all subsequent analyses reflect post-matching results. CFA cycles demonstrated a superior ovarian response, with significantly higher total oocyte yield (5.30±2.96 vs 4.53±2.65, p = 0.019) and more good-quality Day 3 embryos (2.23±1.90 vs 1.79±2.06, p = 0.049). Although MII oocytes, 2PN zygotes, and total Day 3 embryos were numerically higher in the CFA group, these differences did not reach statistical significance. Blastocyst-stage outcomes, including total and good-quality Day 5 embryos, were comparable between groups. Among fresh embryo transfer cycles (n = 69), CFA cycles showed higher clinical pregnancy (42.9% vs 21.8%), fetal heartbeat (42.9% vs 16.7%), and live birth rates (35.7% vs 16.4%), although none reached statistical significance. No cases of ovarian hyperstimulation syndrome were observed. Limitations, reasons for caution The retrospective design and limited number of fresh transfer cycles restrict generalizability. Variability in transfer policies and residual confounding may affect outcomes. Prospective randomized trials are required for validation. Wider implications of the findings CFA represents a patient-friendly alternative to daily injections in poor responders, offering improved oocyte and embryo yield with encouraging pregnancy trends. This simplified approach may facilitate individualized IVF strategies and enhance patient experience. Trial registration number No

Zitieren

APA

Luong, T., Lee, J., Ho, N., Hwu, Y., Ho, J., Wang, R., Tan, S., Lee, Y., Huang, H., Le, N., & Tzeng, C. (2026). L26/P-695 Long-acting FSH (corifollitropin alfa) improves ovarian response in poor responders undergoing IVF: a propensity-matched cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1024

Vancouver

Luong T, Lee J, Ho N, Hwu Y, Ho J, Wang R, et al. L26/P-695 Long-acting FSH (corifollitropin alfa) improves ovarian response in poor responders undergoing IVF: a propensity-matched cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1024

BibTeX
@article{Luong2026,
  author = {Luong, T.M.T. and Lee, J.H. and Ho, N.T. and Hwu, Y.M. and Ho, J.Y.P. and Wang, R.S. and Tan, S.J. and Lee, Y.X. and Huang, H.H. and Le, N.Q.K. and Tzeng, C.R.},
  title = {L26/P-695 Long-acting FSH (corifollitropin alfa) improves ovarian response in poor responders undergoing IVF: a propensity-matched cohort study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1024}
}
Kostenlos starten →